4.6 Article

Isoform-Selective ATAD2 Chemical Probe with Novel Chemical Structure and Unusual Mode of Action

期刊

ACS CHEMICAL BIOLOGY
卷 12, 期 11, 页码 2730-2736

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acschembio.7b00708

关键词

-

资金

  1. AbbVie [1097737]
  2. Bayer Pharma AG
  3. Boehringer Ingelheim
  4. Canada Foundation for Innovation
  5. Eshelman Institute for Innovation
  6. Genome Canada
  7. Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD] [115766]
  8. Janssen
  9. Merck Co.
  10. Novartis Pharma AG
  11. Ontario Ministry of Economic Development and Innovation
  12. Pfizer
  13. Sao Paulo Research Foundation-FAPESP
  14. Takeda
  15. Wellcome Trust [106169/ZZ14/Z]

向作者/读者索取更多资源

ATAD2 (ANCCA) is an epigenetic regulator and transcriptional cofactor, whose overexpression has been linked to the progress of various cancer types. Here, we report a DNA-encoded library screen leading to the discovery of BAY-850, a potent and isoform selective inhibitor that specifically induces ATAD2 bromodomain dimerization and prevents interactions with acetylated histones in vitro, as well as with chromatin in cells. These features qualify BAY-850 as a chemical probe to explore ATAD2 biology.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据